Researchers are excited about the medication , a groundbreaking dual agonist showing remarkable data in initial trials for size management. It works by targeting both systems: GLP-1 and GIP, that , when activated , assist control hunger and enhance energy expenditure . Initial observations suggest considerable size management and potential improvem